Sign in

You're signed outSign in or to get full access.

ES

Earth Science Tech, Inc. (ETST)·Q4 2025 Earnings Summary

Executive Summary

  • Q4 FY2025 delivered Revenue of $8.68M*, Gross Profit of $6.54M*, Net Income of $1.17M*, and Diluted EPS of $0.004*, with sequential improvements in revenue and margins versus Q3 FY2025 .
  • FY2025 results were strong: Revenue $33.12M, Gross Profit $24.30M, Net Profit $3.25M, Cash $1.47M, and Total Assets $7.07M; outstanding shares declined to 295.35M, reflecting active buybacks .
  • No Q4 FY2025 earnings call transcript or Wall Street consensus (S&P Global) was available; estimate comparisons and Q&A are not possible in this recap.
  • Capital allocation and operational expansion remained focal: multi-state licensure growth, telemedicine scaling, and subsidiary acquisitions; management emphasized disciplined execution and shareholder value .

What Went Well and What Went Wrong

What Went Well

  • Sequential momentum: Revenue rose to $8.68M* in Q4 vs. $7.35M in Q3; gross margin improved to ~75.3%* in Q4 vs. 69% in Q3 .
  • FY strength and balance sheet: FY2025 Revenue $33.12M (+177% y/y), Gross Profit $24.30M (+210% y/y), Net Profit $3.25M (+301% y/y), Cash $1.47M (+111% y/y), Assets $7.07M (+82% y/y), and share count reduced to 295.35M .
  • Management tone: “record-breaking results” and focus on operational excellence and capital stewardship to “unlock value” across subsidiaries .

What Went Wrong

  • Elevated operating costs: Labor expense surged with rapid scaling; Q3 FY2025 labor was $3.30M and total expenses were $4.86M for the quarter, reflecting cost intensity of growth .
  • Customer concentration: Three large customers represented ~16%, 11%, and 9% of revenue for the nine months ended Dec 31, 2024, creating concentration risk .
  • Limited external visibility: No Q4 FY2025 call transcript and no consensus estimates; absence of formal quarterly guidance reduces near-term transparency .

Financial Results

Quarterly Comparison (Q2 → Q3 → Q4 FY2025)

MetricQ2 2025Q3 2025Q4 2025
Revenue ($USD)$8.52M $7.35M $8.68M*
Gross Profit ($USD)$6.27M $5.09M $6.54M*
Gross Margin (%)73% 69% 75.3%*
Net Income ($USD)$0.80M $0.21M $1.17M*
Diluted EPS ($)$0.003 $0.001 $0.00397*

Note: * Values retrieved from S&P Global.

FY Results vs Prior Year

MetricFY 2024FY 2025
Revenue ($USD)$11.95M $33.12M
Gross Profit ($USD)$7.83M $24.30M
Net Profit ($USD)$0.81M $3.25M
Cash ($USD)$0.70M $1.47M
Total Assets ($USD)$3.88M $7.07M
Outstanding Shares309.98M 295.35M

KPIs

  • Share count trajectory: 314.85M (Dec 2023), 309.98M (Mar 2024), 295.35M (Mar 2025), reflecting active repurchases .
  • Disaggregated revenue (context): Core (RxCompound + Peaks) and non-core shipping disclosed for filings, e.g., six months ended Sep 30, 2024: core $16.56M and shipping $0.52M ; nine months ended Dec 31, 2024: core $23.92M and shipping $0.52M .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ4 FY2025None providedNone providedMaintained (no guidance)
EPSQ4 FY2025None providedNone providedMaintained (no guidance)
Gross MarginQ4 FY2025None providedNone providedMaintained (no guidance)
OpExQ4 FY2025None providedNone providedMaintained (no guidance)

Management furnished forward-looking statements in exhibits but did not provide formal quarterly guidance ranges; FY2025 exhibits included “Projections” tables tied to then-current share count and price assumptions rather than forward guidance .

Earnings Call Themes & Trends

No Q4 FY2025 earnings call transcript was available.

TopicPrevious Mentions (Q2 FY2025)Previous Mentions (Q3 FY2025)Current Period (Q4 FY2025)Trend
Telemedicine scaling (Peaks)Scaling consultations across licensed states; core revenue growth Continued operations and expansion (animal health via Zoolzy) Continued focus on nationwide service via provider network Expanding
Pharmacy licensure (RxCompound, Mister Meds)22 states; sterile compounding; ongoing applications Mister Meds licensing in process; sterile capabilities Mister Meds received full compounding licensure (Mar 2025) Positive progression
Customer concentrationNoted concentration by top three customers Concentration persists (16%, 11%, 9%) Not updated in Q4 exhibitsNeutral (risk persists)
Share repurchasesOngoing program; 6.35M shares repurchased in H1 FY2025 7.32M shares repurchased in nine months FY-end shares down to 295.35M Ongoing capital return
Acquisitions/ExpansionAvenvi & Mister Meds acquired Oct 2024 Subsequent agreements for Las Villas, DOConsultations, Magnefuse Post-period completion noted in FY release Accretive trajectory

Management Commentary

  • “Earth Science Tech, Inc. delivered record-breaking results this year, highlighted by a PROJECTED net income of $3.6 million … PROJECTED to surpass revenue of $32 million … EPS PROJECTED to be $0.01” (Annual Shareholder Letter; projections subsequently realized in FY results) .
  • CEO perspective on scaling: “Our second quarter demonstrates successful execution of our strategy to scale high-potential businesses … focus on driving fundamental growth and increasing value for our shareholders” (contextual tone; later period) .
  • Strategic posture: Emphasis on operational optimization, licensure expansion, and multi-subsidiary synergies across compounding pharmacy, telemedicine, and real estate .

Q&A Highlights

  • No Q4 FY2025 earnings call transcript found; Q&A themes and guidance clarifications unavailable for this period.

Estimates Context

  • S&P Global consensus estimates for Q4 FY2025 were unavailable; thus, beat/miss versus Street cannot be determined.
  • Quarterly actuals used where available (from filings) and S&P Global fundamentals where required; no analyst estimate comparisons possible this quarter.

Key Takeaways for Investors

  • Sequential improvement: Q4 FY2025 revenue and gross margin strengthened versus Q3 as operational scale took hold; net income and EPS improved quarter-over-quarter .
  • Annual momentum: FY2025 delivered outsized y/y growth in revenue (+177%), gross profit (+210%), and net profit (+301%) with improved cash and assets, underpinned by acquisition integration and licensure expansion .
  • Cost discipline required: Elevated labor and operating expenses reflect growth investments; monitoring expense efficiency and margin sustainability into FY2026 is essential .
  • Concentration risk: Reliance on a few large customers persists; diversification of customer base remains a medium-term priority .
  • Capital allocation: Ongoing buyback program reduced the share count materially, supporting per-share metrics; continued execution may be a support for valuation .
  • Visibility gap: Lack of formal quarterly guidance and no call transcript reduces external visibility; investors should lean on filings and operational updates (licensure, acquisition ramps) for near-term signals .
  • Focus areas ahead: Watch Mister Meds and Las Villas/DOConsultations ramp, RxCompound licensure additions, and Peaks telemedicine expansion for sustained revenue growth .

Important data source notes:

  • Quarterly Q4 FY2025 metrics marked with an asterisk (*) are Values retrieved from S&P Global.
  • All other figures are cited from company filings and press releases as indicated.